Amolyt Pharma (formerly known as Alizé Pharma) is a company that specializes in the development of biopharmaceutical drugs, proteins, and peptides for the treatment of metabolic diseases and cancer. It has two programs, the AZP-3601, a PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for the treatment of syndromes of acute insulin resistance.